MainStreet Investment Advisors LLC Buys Shares of 6,044 Abbott Laboratories $ABT

MainStreet Investment Advisors LLC acquired a new stake in shares of Abbott Laboratories (NYSE:ABT) in the third quarter, HoldingsChannel reports. The firm acquired 6,044 shares of the healthcare product maker’s stock, valued at approximately $810,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Brighton Jones LLC boosted its holdings in shares of Abbott Laboratories by 10.1% in the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after purchasing an additional 4,755 shares during the period. Sivia Capital Partners LLC increased its stake in shares of Abbott Laboratories by 3.5% during the second quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock valued at $648,000 after buying an additional 162 shares during the period. United Bank raised its holdings in shares of Abbott Laboratories by 7.4% in the second quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock valued at $3,945,000 after acquiring an additional 2,001 shares in the last quarter. 180 Wealth Advisors LLC lifted its stake in Abbott Laboratories by 12.7% in the second quarter. 180 Wealth Advisors LLC now owns 2,038 shares of the healthcare product maker’s stock worth $277,000 after acquiring an additional 229 shares during the period. Finally, Curio Wealth LLC raised its holdings in shares of Abbott Laboratories by 15,250.0% in the 2nd quarter. Curio Wealth LLC now owns 307 shares of the healthcare product maker’s stock valued at $42,000 after purchasing an additional 305 shares in the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on the stock. Evercore cut their price objective on shares of Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Weiss Ratings cut Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, January 26th. Sanford C. Bernstein decreased their price objective on Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating for the company in a research note on Friday, January 23rd. Argus decreased their price target on shares of Abbott Laboratories from $150.00 to $140.00 in a research report on Tuesday, January 27th. Finally, William Blair raised shares of Abbott Laboratories to a “strong-buy” rating in a research report on Thursday, November 20th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, Abbott Laboratories has an average rating of “Moderate Buy” and a consensus target price of $137.05.

More Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Exact Sciences stockholders approved Abbott’s acquisition proposal (preliminary results showed >99% of votes cast and ~67% of outstanding shares represented), clearing a key shareholder hurdle and advancing Abbott’s expansion into cancer screening/diagnostics — a strategic deal that should broaden revenue mix and long-term growth prospects. Exact Sciences Stockholders Approve Acquisition by Abbott
• Positive Sentiment: Abbott’s board declared its 409th consecutive quarterly dividend at $0.63/share, reinforcing a reliable income profile that supports shareholder confidence and may attract income-oriented investors. Abbott declares 409th consecutive quarterly dividend
• Positive Sentiment: Abbott reported positive clinical results for its Amulet 360 Left Atrial Appendage (LAA) occluder presented at the AF Symposium — a favorable outcome for the company’s structural-heart/device pipeline that could support future market adoption and revenue growth in electrophysiology/cardiology. Abbott Laboratories (ABT) Announces Positive Results for Amulet 360 Left Atrial Appendage (LAA) Occlude
• Neutral Sentiment: Abbott’s board approved governance changes to streamline the board (smaller board size). This is a modest corporate-governance move that could slightly improve oversight/efficiency but is unlikely to drive material near-term earnings changes. Abbott Laboratories Streamlines Governance With Smaller Board
• Neutral Sentiment: Media comparisons (BSX vs ABT) highlight Abbott’s valuation appeal, CGM momentum and strategic deals as advantages vs. Boston Scientific — useful context for investors but not a direct corporate action. BSX vs. ABT: Which MedTech Stock is the Better Investment Now?
• Negative Sentiment: BTIG cut its price target for ABT to $140, which may temper near-term analyst-driven upside and investor enthusiasm despite the company’s strategic wins; analyst revisions can influence sentiment and trading volume. BTIG Research Cuts Abbott Laboratories (NYSE:ABT) Price Target to $140.00

Abbott Laboratories Price Performance

Shares of NYSE ABT opened at $112.21 on Monday. Abbott Laboratories has a 52 week low of $105.27 and a 52 week high of $141.23. The company has a quick ratio of 1.24, a current ratio of 1.70 and a debt-to-equity ratio of 0.23. The firm has a market cap of $195.11 billion, a P/E ratio of 30.16, a P/E/G ratio of 1.79 and a beta of 0.75. The business’s 50 day moving average price is $118.46 and its 200 day moving average price is $125.80.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, meeting the consensus estimate of $1.50. The business had revenue of $11.46 billion for the quarter, compared to the consensus estimate of $11.80 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.94%. The business’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same period in the prior year, the firm earned $1.34 EPS. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, sell-side analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a $0.63 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.2%. Abbott Laboratories’s dividend payout ratio is 67.74%.

Insider Activity

In other Abbott Laboratories news, Director Daniel J. Starks bought 10,000 shares of the company’s stock in a transaction dated Wednesday, February 4th. The shares were purchased at an average cost of $108.73 per share, for a total transaction of $1,087,300.00. Following the transaction, the director directly owned 6,738,817 shares of the company’s stock, valued at approximately $732,711,572.41. The trade was a 0.15% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.46% of the stock is currently owned by insiders.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.